You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 2, 2024

~ Buy the XALKORI (crizotinib) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR XALKORI

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for XALKORI

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00939770 ↗	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2009-09-21	This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT00939770 ↗	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	Pfizer	Phase 1/Phase 2	2009-09-21	This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT00939770 ↗	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	Children's Oncology Group	Phase 1/Phase 2	2009-09-21	This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for XALKORI

Condition Name

Chart
Table

Condition Name for XALKORI
Intervention	Trials
Refractory Malignant Solid Neoplasm	4
Advanced Malignant Solid Neoplasm	4
Carcinoma, Non-Small-Cell Lung	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for XALKORI
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	18
Lung Neoplasms	14
Neoplasms	12
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for XALKORI

Trials by Country

Map
Table

Trials by Country for XALKORI
Location	Trials
United States	543
China	51
Japan	27
Canada	24
Italy	23
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for XALKORI
Location	Trials
Texas	20
New York	19
Pennsylvania	18
Florida	17
California	17
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for XALKORI

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for XALKORI
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	6
Phase 2/Phase 3	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for XALKORI
Clinical Trial Phase	Trials
Recruiting	17
Active, not recruiting	11
Completed	9
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for XALKORI

Sponsor Name

Chart
Table

Sponsor Name for XALKORI
Sponsor	Trials
Pfizer	23
National Cancer Institute (NCI)	14
M.D. Anderson Cancer Center	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for XALKORI
Sponsor	Trials
Industry	58
Other	43
NIH	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.